TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

IFEX

IFOSFAMIDE Alkylating Activity
Oncology Approved 1987-08-14
1
Indication
--
Phase 3 Trials
1
Priority Reviews
38
Years on Market

Details

Status
Prescription
First Approved
1987-08-14
Routes
INJECTION
Dosage Forms
INJECTABLE

Companies

Active Ingredient: IFOSFAMIDE

IFEX Approval History

Loading approval history...

What IFEX Treats

1 indications

IFEX is approved for 1 conditions since its original approval in 1987. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Testicular Cancer
Source: FDA Label

IFEX Boxed Warning

MYELOSUPPRESSION, ENCEPHALOPATHY, NEPHROTOXICITY and UROTOXICITY • Myelosuppression can be severe and lead to fatal infections. Monitor blood counts prior to and at intervals after each treatment cycle [see Warnings and Precautions (5.1) ] . • Encephalopathy can be severe and may result in death. Monitor for CNS toxicity and discontinue treatment for encephalopathy [see Warnings and Precautions (5.2) ] . • Nephrotoxicity can be severe and result in renal failure. Hemorrhagic cystitis can be seve...

🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

IFEX FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

IFEX is indicated for use in adults in combination with certain other approved antineoplastic agents for third-line chemotherapy of germ cell testicular cancer. IFEX is an alkylating drug indicated for use in adults in combination with certain other approved antineoplastic agents for third-line chemotherapy of germ cell testicular cancer.

⚠️ BOXED WARNING

WARNING: MYELOSUPPRESSION, ENCEPHALOPATHY, NEPHROTOXICITY and UROTOXICITY • Myelosuppression can be severe and lead to fatal infections. Monitor blood counts prior to and at intervals after each treatment cycle [see Warnings and Precautions (5.1) ] . • Encephalopathy can be severe and may result in ...

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.